AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22162508 — intervention group
Group type: EXPERIMENTAL
Intervention: lacosamide (200 mg bid) with early or late addition of valproic acid (300 mg bid)
Number of subjects: 32
Study 20237130 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the posterior hypothalamus
Number of subjects: 10
Study 17346530 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (metronidazole plus azithromycin)
Number of subjects: 241
Study 15709825 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflated responsibility in the context of negative mood
Number of subjects: 0
Study 15709825 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 0
Study 15709825 — intervention group
Group type: COMPARATOR
Intervention: Inflated responsibility alone
Number of subjects: 0
Study 11903074 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-treated propofol group
Number of subjects: 40
Study 11903074 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-treated isoflurane group
Number of subjects: 40
Study 11903074 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-based anesthesia without amino acids
Number of subjects: 40
Study 11903074 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based anesthesia without amino acids
Number of subjects: 40
Study 11903074 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-treated groups (both propofol and isoflurane)
Number of subjects: 40
Study 9625544 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2-mm incision
Number of subjects: 111
Study 9625544 — intervention group
Group type: COMPARATOR
Intervention: 5.5-mm incision
Number of subjects: 111
Study 7942354 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (750 mg given immediately, followed by 500 mg 6 h later) with tetracycline (250 mg four times daily)
Number of subjects: 102
Study 7942354 — intervention group
Group type: COMPARATOR
Intervention: Quinine (600 mg every 8 h for seven days) with tetracycline (250 mg four times daily)
Number of subjects: 102
Study 3203964 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 11
Study 3203964 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour diagnostic continuous electrocardiographic and high fidelity arterial pressure monitoring in hypertensive group (n=7)
Number of subjects: 11
Study 3203964 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour diagnostic continuous electrocardiographic and high fidelity arterial pressure monitoring
Number of subjects: 11
Study 31415392 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized occlusal splint therapy applied during day‐ and nighttime plus usual care (n=30)
Number of subjects: 60
Study 31415392 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n=30)
Number of subjects: 60
Study 29793433 — intervention group
Group type: EXPERIMENTAL
Intervention: List randomization (Arm A)
Number of subjects: 483
Study 29793433 — intervention group
Group type: COMPARATOR
Intervention: Direct estimates (Arm B)
Number of subjects: 483
Study 29793433 — intervention group
Group type: COMPARATOR
Intervention: Direct estimation (Arm B)
Number of subjects: 483
Study 29793433 — intervention group
Group type: COMPARATOR
Intervention: Observed past behavior
Number of subjects: 483
Study 26888164 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA)
Number of subjects: 19
Study 26888164 — intervention group
Group type: COMPARATOR
Intervention: Colesevelam
Number of subjects: 19
Study 26888164 — intervention group
Group type: COMPARATOR
Intervention: CDCA + colesevelam
Number of subjects: 19
Study 26888164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 24065294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination exercise training (aerobic, strength, and stretching exercise trainings) 3 days per week for 4 weeks (12 workouts total)
Number of subjects: 64
Study 24065294 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 64
Study 22520733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy combined with bevacizumab and erlotinib
Number of subjects: 26
Study 19862578 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider decision support and patient decision support
Number of subjects: 7412
Study 17928625 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg daily)
Number of subjects: 22
Study 17928625 — intervention group
Group type: COMPARATOR
Intervention: Quinapril (20 mg daily)
Number of subjects: 22
Study 15647105 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir 300 mg twice daily
Number of subjects: 104
Study 15647105 — intervention group
Group type: COMPARATOR
Intervention: PI continuation
Number of subjects: 104
Study 11901939 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic and ACE inhibitor combination
Number of subjects: 0
Study 11901939 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor alone
Number of subjects: 0
Study 9853849 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 37462 (ganirelix) 0.0625 mg
Number of subjects: 333
Study 9853849 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 37462 (ganirelix) 0.125 mg
Number of subjects: 333
Study 9853849 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 37462 (ganirelix) 0.25 mg
Number of subjects: 333
Study 9853849 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 37462 (ganirelix) 2 mg
Number of subjects: 333
Study 9853849 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 37462 (ganirelix) 1 mg
Number of subjects: 333
Study 8281697 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 512
Study 8281697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 3354872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg preservative-free morphine sulfate in 0.2 ml solution added to hyperbaric spinal bupivacaine
Number of subjects: 34
Study 3354872 — intervention group
Group type: COMPARATOR
Intervention: 0.2 ml saline added to bupivacaine (Control)
Number of subjects: 34
Study 18716627 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey (pHW) preterm infant formula
Number of subjects: 80
Study 18716627 — intervention group
Group type: COMPARATOR
Intervention: Standard nonhydrolyzed whey‐casein (nHWC) preterm infant formula
Number of subjects: 80
Study 7351070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmozin 225 mg/day (Group 1)
Number of subjects: 37
Study 7351070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmozin 600 mg/day (Group 2)
Number of subjects: 37
Study 7351070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single-blind, only to responders)
Number of subjects: 37
Study 30946599 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-family environment interactions (G×FE) message
Number of subjects: 324
Study 30946599 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetics only message
Number of subjects: 324
Study 30946599 — intervention group
Group type: EXPERIMENTAL
Intervention: Family environment only message
Number of subjects: 324
Study 30946599 — intervention group
Group type: COMPARATOR
Intervention: Control article
Number of subjects: 324
Study 28215945 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), 1.5g/d for 6 months and prednisone, 0.4 to 0.6mg/kg/d for 2 months, then tapered by 20% per month for the next 4 months
Number of subjects: 176
Study 28215945 — intervention group
Group type: COMPARATOR
Intervention: Prednisone, 0.8 to 1.0mg/kg/d for 2 months, then tapered by 20% per month for the next 4 months
Number of subjects: 176
Study 26415375 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (750 mg once daily for 10 days)
Number of subjects: 40
Study 24091269 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal group (drainage < 300 ml/24 h), n = 41
Number of subjects: 70
Study 24091269 — intervention group
Group type: COMPARATOR
Intervention: Traditional management group (drainage < 100 ml/24 h), n = 29
Number of subjects: 70
Study 22044691 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel addition to adjuvant anthracycline-based chemotherapy
Number of subjects: 1099
Study 22044691 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel addition
Number of subjects: 1099
Study 19220626 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention
Number of subjects: 0
Study 19220626 — intervention group
Group type: EXPERIMENTAL
Intervention: Harsh parenting, responsive parenting, and stimulating parenting improvements
Number of subjects: 0
Study 19070056 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (20 mg day(‐1))
Number of subjects: 79
Study 19070056 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg day(‐1))
Number of subjects: 79
Study 19070056 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron + Zinc supplementation (20 mg of each day(‐1))
Number of subjects: 79
Study 19070056 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 79
Study 15219777 — intervention group
Group type: EXPERIMENTAL
Intervention: lamotrigine (300 mg)
Number of subjects: 15
Study 15219777 — intervention group
Group type: EXPERIMENTAL
Intervention: 4030W92 (100 mg)
Number of subjects: 15
Study 15219777 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 15219777 — intervention group
Group type: EXPERIMENTAL
Intervention: lamotrigine or 4030W92
Number of subjects: 15
Study 11581138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 827
Study 11581138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827
Study 9626282 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight support (BWS) system with overhead harness, supporting up to 40% of body weight
Number of subjects: 100
Study 9626282 — intervention group
Group type: COMPARATOR
Intervention: No body weight support (no-BWS), bearing full weight on lower extremities
Number of subjects: 100
Study 9626282 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight support (BWS) system with overhead harness
Number of subjects: 100
Study 9626282 — intervention group
Group type: COMPARATOR
Intervention: No body weight support (no-BWS)
Number of subjects: 100
Study 7942679 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Number of subjects: 178
Study 7942679 — intervention group
Group type: EXPERIMENTAL
Intervention: upper endoscopy
Number of subjects: 178
Study 7942679 — intervention group
Group type: COMPARATOR
Intervention: none
Number of subjects: 178
Study 3232497 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride 50 mg intravenously
Number of subjects: 170
Study 3232497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 29193743 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized Early Intervention (SEI) treatment (OPUS treatment)
Number of subjects: 0
Study 29193743 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity scale for SEI teams
Number of subjects: 0
Study 29193743 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity scale components
Number of subjects: 0
Study 28648698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (D + T)
Number of subjects: 563
Study 26303617 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Affluence Scale for Children (HASC) <2.0
Number of subjects: 422
Study 24373262 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Behavioral Modification based on the Client Center Program (HBMCCP) for 8 weeks
Number of subjects: 59
Study 24373262 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Behavioral Modification based on the Client Center Program (HBMCCP)
Number of subjects: 59
Study 24373262 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 22018484 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tilt biphasic waveform (LTBW)
Number of subjects: 30
Study 22018484 — intervention group
Group type: COMPARATOR
Intervention: Low-tilt monophasic waveform (LTMW)
Number of subjects: 30
Study 22018484 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover patients (after initial waveform failure)
Number of subjects: 30
Study 22018484 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean voltage, current, and energy used for cardioversion
Number of subjects: 30
Study 22018484 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful cardioversion patients
Number of subjects: 30
Study 22018484 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse complications
Number of subjects: 30
Study 22018484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac markers measured postcardioversion
Number of subjects: 30
Study 19791470 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 78
Study 19791470 — intervention group
Group type: COMPARATOR
Intervention: Non-statin
Number of subjects: 78
Study 16828596 — intervention group
Group type: EXPERIMENTAL
Intervention: RV apical pacing
Number of subjects: 56
Study 16828596 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline variables (age, gender, history of heart failure, QRS duration in spontaneous rhythm and during pacing, LV end-diastolic and end-systolic diameters, LV ejection fraction, and intra-LV EMD in spontaneous rhythm)
Number of subjects: 56
Study 12547469 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride (5 mg p.o. twice daily)
Number of subjects: 40
Study 12547469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10362076 — intervention group
Group type: EXPERIMENTAL
Intervention: HME
Number of subjects: 64
Study 10362076 — intervention group
Group type: COMPARATOR
Intervention: CH
Number of subjects: 64
Study 7488417 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus hydroxyzine hydrochloride (group G/H)
Number of subjects: 0
Study 7488417 — intervention group
Group type: COMPARATOR
Intervention: Granisetron alone (group G)
Number of subjects: 0
Study 1663466 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (total dose 1.5 g, given orally in five or six doses over 5 days)
Number of subjects: 0
Study 1663466 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (500 mg orally four times daily for 7 days)
Number of subjects: 0
Study 1663466 — intervention group
Group type: COMPARATOR
Intervention: Cloxacillin (500 mg orally four times daily for 7 days)
Number of subjects: 0
Study 1663466 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 1663466 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 0
Study 1663466 — intervention group
Group type: COMPARATOR
Intervention: Cloxacillin
Number of subjects: 0
Study 7103522 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinitrochlorobenzene (DNCB) treatment applied locally in two forms: an acetone solution applied weekly or a cream used every day, with varying concentrations to induce contact dermatitis.
Number of subjects: 42
Study 7103522 — intervention group
Group type: EXPERIMENTAL
Intervention: DNCB treatment with cimetidine administration to abolish acquired tolerance.
Number of subjects: 42
Study 30427250 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 0
Study 29108741 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavour-Texture (taste, smell, and texture)
Number of subjects: 194
Study 29108741 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavour (taste and smell)
Number of subjects: 194
Study 29108741 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste only
Number of subjects: 194
Study 29108741 — intervention group
Group type: EXPERIMENTAL
Intervention: Smell only
Number of subjects: 194
Study 29108741 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture cues in addition to flavour cues for carrot, cucumber, onion, and tomato
Number of subjects: 194
Study 29108741 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased perceived intensity of smell, taste, or flavour cues
Number of subjects: 194
Study 27160841 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU Nurse-Physician Questionnaire (ICU N-P-Q) administered to physicians and nurses
Number of subjects: 2006
Study 27160841 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU N-P-Q
Number of subjects: 2006
Study 25115761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH; reviparin)
Number of subjects: 365
Study 25115761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 22978047 — intervention group
Group type: COMPARATOR
Intervention: Kramer's index
Number of subjects: 50
Study 20939236 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid
Number of subjects: 1521
Study 20939236 — intervention group
Group type: COMPARATOR
Intervention: Cervical cytology
Number of subjects: 1521
Study 18556849 — intervention group
Group type: EXPERIMENTAL
Intervention: TINTARA uterine manipulator
Number of subjects: 60
Study 18556849 — intervention group
Group type: COMPARATOR
Intervention: Cohen cannula
Number of subjects: 60
Study 16046894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance and movement program (The Lebed Method, Focus on Healing Through Movement and Dance) for 12 weeks
Number of subjects: 35
Study 16046894 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 35
Study 16046894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance and movement program (The Lebed Method, Focus on Healing Through Movement and Dance)
Number of subjects: 35
Study 12464949 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg daily)
Number of subjects: 782
Study 12464949 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (200 microg twice daily)
Number of subjects: 782
Study 12464949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 782
Study 10726437 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (R)
Number of subjects: 8
Study 10726437 — intervention group
Group type: COMPARATOR
Intervention: Swimming (S)
Number of subjects: 8
Study 8749592 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D corrugated surface detection
Number of subjects: 2
Study 8749592 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion coherence task
Number of subjects: 2
Study 1782137 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT assay for CF screening
Number of subjects: 0
Study 7299001 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oil (1, 2, and 5 ml doses)
Number of subjects: 10
Study 7299001 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 10
Study 31675540 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone training program (once a week for 20 weeks)
Number of subjects: 344
Study 31675540 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no training during the study period)
Number of subjects: 344
Study 30448776 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for 5 days and iron-MNPs for 40 days (Fe+Ab+)
Number of subjects: 28
Study 30448776 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics and no-iron-MNPs (Fe-Ab+)
Number of subjects: 28
Study 30448776 — intervention group
Group type: EXPERIMENTAL
Intervention: No antibiotics and iron-MNPs (Fe+Ab-)
Number of subjects: 28
Study 30448776 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics and no-iron-MNPs (Fe-Ab-)
Number of subjects: 28
Study 30448776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe+Ab+
Number of subjects: 28
Study 28668686 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART initiation
Number of subjects: 4629
Study 27589688 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2+GM‐CSF
Number of subjects: 180
Study 27589688 — intervention group
Group type: COMPARATOR
Intervention: GM‐CSF alone
Number of subjects: 180
Study 25000595 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPRA
Number of subjects: 25
Study 25000595 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP
Number of subjects: 25
Study 25000595 — intervention group
Group type: EXPERIMENTAL
Intervention: S30SRP
Number of subjects: 25
Study 21720723 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-switching tasks (visual and auditory)
Number of subjects: 18
Study 20969925 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg VAX125 vaccine
Number of subjects: 128
Study 20969925 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 μg VAX125 vaccine
Number of subjects: 128
Study 20969925 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg VAX125 vaccine
Number of subjects: 128
Study 20969925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 17990465 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy of DCF regimen combined with Chinese herbal medicine
Number of subjects: 66
Study 17990465 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy of DCF regimen alone
Number of subjects: 66
Study 15792884 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz repetitive transcranial magnetic stimulation (rTMS) over left pre-motor cortex
Number of subjects: 5
Study 15792884 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz repetitive transcranial magnetic stimulation (rTMS) over left pre-motor cortex followed by right pre-motor cortex
Number of subjects: 5
Study 15792884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned in the abstract)
Number of subjects: 5
Study 12144714 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholegrain diet
Number of subjects: 11
Study 12144714 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain diet
Number of subjects: 11
Study 10189457 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mL of 60% iodinated contrast material injected at 2 mL/sec (group 1)
Number of subjects: 75
Study 10189457 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mL of 60% iodinated contrast material injected at 3 mL/sec (group 2)
Number of subjects: 75
Study 10189457 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of 60% iodinated contrast material injected at 3 mL/sec (group 3)
Number of subjects: 75
Study 1446494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin, rifampicin, and isoniazid
Number of subjects: 124
Study 1446494 — intervention group
Group type: COMPARATOR
Intervention: Ethambutol, rifampicin, and isoniazid
Number of subjects: 124